Jupiter Bioscience Of India Seeks U.S., Europe Acquisitions
This article was originally published in PharmAsia News
Executive Summary
India's Jupiter Bioscience says it is discussing with several companies as possible acquisition targets to build its strength in the United States and Europe. The firm plans to spend about $15 million through the coming year to acquire a company in each of the two markets. Jupiter Chairman Venkat Kalavakolanu did not name firms it was talking to, but said some are high-end research companies specializing in peptides and others specialize in building-blocks. (Click here for more